2.50
Hdl Handle:
http://hdl.handle.net/10541/99271
Title:
Chemotherapy in non-small cell lung cancer.
Authors:
Thatcher, Nick; Ranson, Malcolm R; Lee, Siow Ming; Niven, Robert McL; Anderson, Heather
Abstract:
BACKGROUND: Non-small cell lung cancer can no longer be regarded as resistant to chemotherapy, and there have recently been considerable improvements in the use of the older agents and advances in the identification of new drugs. Recent meta-analysis has also confirmed the view that chemotherapy can have small but modest survival benefits. Although in the treatment of stage IV disease the criteria of efficacy have concentrated on tumour response rates, more recently it has become obvious that these patients can also benefit in terms of improved symptom control. RECENT ADVANCES: For patients with locally advanced stage III disease there have been important developments indicating the benefit of combined modality treatment with chemotherapy and thoracic irradiation. Furthermore, the use of neoadjuvant chemotherapy indicates that resection is possible in about half the patients, and on pathological examination of 15%-20% of the resected specimens there is no evidence of residual tumour. These results justify an increase in the use of systemic chemotherapy in this disease.
Affiliation:
CRC Department of Medical Oncology, Christie Hospital, Manchester, U.K.
Citation:
Chemotherapy in non-small cell lung cancer. 1995, 6 Suppl 1:83-94; discussion 94-5 Ann. Oncol.
Journal:
Annals of Oncology
Issue Date:
1995
URI:
http://hdl.handle.net/10541/99271
PubMed ID:
8695551
Type:
Article
Language:
en
ISSN:
0923-7534
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorThatcher, Nicken
dc.contributor.authorRanson, Malcolm Ren
dc.contributor.authorLee, Siow Mingen
dc.contributor.authorNiven, Robert McLen
dc.contributor.authorAnderson, Heatheren
dc.date.accessioned2010-05-19T10:21:29Z-
dc.date.available2010-05-19T10:21:29Z-
dc.date.issued1995-
dc.identifier.citationChemotherapy in non-small cell lung cancer. 1995, 6 Suppl 1:83-94; discussion 94-5 Ann. Oncol.en
dc.identifier.issn0923-7534-
dc.identifier.pmid8695551-
dc.identifier.urihttp://hdl.handle.net/10541/99271-
dc.description.abstractBACKGROUND: Non-small cell lung cancer can no longer be regarded as resistant to chemotherapy, and there have recently been considerable improvements in the use of the older agents and advances in the identification of new drugs. Recent meta-analysis has also confirmed the view that chemotherapy can have small but modest survival benefits. Although in the treatment of stage IV disease the criteria of efficacy have concentrated on tumour response rates, more recently it has become obvious that these patients can also benefit in terms of improved symptom control. RECENT ADVANCES: For patients with locally advanced stage III disease there have been important developments indicating the benefit of combined modality treatment with chemotherapy and thoracic irradiation. Furthermore, the use of neoadjuvant chemotherapy indicates that resection is possible in about half the patients, and on pathological examination of 15%-20% of the resected specimens there is no evidence of residual tumour. These results justify an increase in the use of systemic chemotherapy in this disease.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAntineoplastic Agents-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshChemotherapy, Adjuvant-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms-
dc.subject.meshPrognosis-
dc.subject.meshSurvival Rate-
dc.titleChemotherapy in non-small cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital, Manchester, U.K.en
dc.identifier.journalAnnals of Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.